Analysts at StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ – Get Free Report) in a report released on Sunday. The firm set a “hold” rating on the medical research company’s stock.
Enzo Biochem Trading Down 0.9 %
Shares of Enzo Biochem stock opened at $1.07 on Friday. The business’s fifty day simple moving average is $1.11 and its 200 day simple moving average is $1.11. Enzo Biochem has a 12 month low of $0.93 and a 12 month high of $1.50.
Institutional Trading of Enzo Biochem
Hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its position in shares of Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after acquiring an additional 64,417 shares in the last quarter. XTX Topco Ltd raised its stake in Enzo Biochem by 94.5% in the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 13,735 shares in the last quarter. BBR Partners LLC purchased a new stake in shares of Enzo Biochem during the 3rd quarter valued at $112,000. Finally, Geode Capital Management LLC lifted its stake in Enzo Biochem by 3.3% during the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after purchasing an additional 11,742 shares during the last quarter. 36.90% of the stock is currently owned by institutional investors.
Enzo Biochem Company Profile
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
Featured Stories
- Five stocks we like better than Enzo Biochem
- What is a Death Cross in Stocks?
- How to Master Trading Discipline: Overcome Emotional Challenges
- How to Most Effectively Use the MarketBeat Earnings Screener
- Trump Tax Reforms: 7 Stocks That Could Benefit in 2025
- How to Choose Top Rated Stocks
- 3 Stocks Near 52-Week Lows: Why They Could Be Smart Buys Today
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.